MCL Literature Feed

Consensus guidelines recommend the BOVen triplet (zanubrutinib, obinutuzumab, venetoclax) for TP53-mutated MCL and CAR-T for BTKi-refractory disease, providing expert guidance for managing high-risk patients.

Preclinical data suggests PRMT5 inhibition is a promising combination therapy strategy for high-risk MCL with ATM and TP53 mutations, which are known to confer therapeutic resistance.

Absence of CD38 expression in conventional nodal MCL strongly correlates with TP53 inactivation and a distinct genetic profile, identifying a high-risk subgroup via routine flow cytometry.

The NAMPT inhibitor KPT-9274 sensitizes TP53-mutated MCL to alkylating chemotherapy by disrupting the DNA damage response, offering a novel combination strategy for this high-risk, chemo-resistant population.

This phase 2 study of frontline acalabrutinib, lenalidomide, and anti-CD20 demonstrates high molecular response rates (67-90%) and 76% 4-year PFS, supporting a time-limited, MRD-driven, chemotherapy-free treatment strategy.

This study demonstrates that TP53 mutation heterogeneity, not just presence, defines distinct prognostic subgroups in MCL, enabling more precise risk stratification beyond a simple binary classification.

This review summarizes the shift towards frontline BTK inhibitor-based regimens, including chemotherapy-free options and combinations for high-risk MCL, potentially replacing autologous stem cell transplant consolidation.

This case report details MCL transformation into CD19-negative classic Hodgkin lymphoma after CAR-T, a novel resistance mechanism driven by immunotherapeutic pressure and lineage plasticity in a high-risk patient.

Real-world data from older Chinese MCL patients shows BTKi-based regimens and maintenance therapy significantly improve survival, validating these strategies for this specific, understudied elderly population.

This large, real-world analysis confirms a dismal prognosis (median OS 5.4 months) for MCL patients progressing after CAR-T, establishing a benchmark for future trials in this high-risk population.

Integrating genomics and spatial proteomics defines three prognostic MCL subtypes, revealing high-risk TP53-mutated tumors are immune-infiltrated yet exhausted, highlighting potential therapeutic vulnerabilities.

A case report of a TP53-deleted splenic marginal zone lymphoma acquiring a secondary CCND1 rearrangement upon high-grade transformation suggests an alternative pathway to cyclin D1-driven lymphomagenesis.

This review advocates for integrating BTK inhibitors into frontline MCL therapy for all patients, particularly for TP53-mutated disease, challenging the standard role of chemotherapy.

Adding venetoclax to RBAC chemo-immunotherapy improves 2-year progression-free survival to 60% for older, high-risk MCL patients, validating a new risk-stratified, fixed-duration frontline treatment.

NCCN guidelines now highlight BTK inhibitor-based regimens as effective options for high-risk, TP53-mutated classical mantle cell lymphoma, formalizing a key strategy for this difficult-to-treat population.

In newly diagnosed MCL, ATM deletion predicts shorter progression-free survival in TP53 wild-type patients, whereas ATM mutation may indicate a better prognosis, highlighting their distinct prognostic roles.

ctDNA sequencing in relapsed/refractory MCL identifies SMARCA4 and TP53 mutations as response predictors and offers more sensitive MRD monitoring than qPCR, improving non-invasive risk stratification.

Comprehensive cfDNA analysis non-invasively tracks MCL disease burden and detects high-risk mutations, offering a powerful liquid biopsy tool for monitoring and risk stratification.

Nodal MCL with leukemic presentation is a high-risk subtype characterized by SOX11-negativity, increased TP53 alterations, and inferior overall survival, requiring distinct clinical consideration.

Digital analysis of p53 immunohistochemistry establishes specific cut-offs (e.g., >50% for 2+/3+ nuclei) that reliably identify TP53 mutations and predict worse survival, improving rapid risk stratification.

This meta-analysis in TP53-mutated MCL supports targeted therapy frontline and CAR-T or transplant in relapse, but confirms poor long-term survival, highlighting the need for novel approaches.

This study identifies predictors of outcome for covalent BTKi therapy in relapsed/refractory TP53-mutant MCL, helping to risk-stratify patients and guide subsequent treatment decisions.

The MCL35 gene expression assay identifies high-risk older patients who do not benefit from adding ibrutinib to bendamustine-rituximab, mandating alternative frontline strategies for this molecularly-defined subgroup.

This review summarizes current MCL risk stratification (MIPI, TP53), highlights emerging genomic biomarkers, and emphasizes MRD monitoring as a key dynamic tool for personalizing therapy, especially for high-risk patients.

In frontline MCL, pre-treatment ctDNA levels and TP53 mutations predict poor survival, while post-treatment ctDNA clearance identifies patients with favorable outcomes, establishing its clinical utility for prognosis.

NGS-detected TP53 mutations are a major clinical risk factor, enabling precise patient stratification to guide initial therapy selection and identify candidates for novel agents.

In high-risk, relapsed/refractory MCL, real-world data shows BTKi plus venetoclax is highly effective, with no added survival benefit from an anti-CD20 monoclonal antibody.

Alternating R-DA-EDOCH/R-DHAP induction for young, newly diagnosed MCL patients achieved an 89% complete remission rate and high MRD negativity, offering a potent new frontline intensive chemotherapy option.

A high-risk, TP53-mutated MCL patient achieved a durable 2-year complete remission with brexucabtagene autoleucel, but developed prolonged severe cytopenias and clonal hematopoiesis, highlighting efficacy and toxicity.

This review summarizes the genomic, molecular, and pathological variations in MCL, highlighting how this biological heterogeneity impacts risk stratification, prognosis, and the development of personalized therapies.